CARGO-CRG-022-101-LBCL
Phase II
OPEN TO ACCRUAL
An Open-label-Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22 Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy